ReP USP - Resultado da busca

Filtros : "Volpiani, Giuliano Giova" Removido: "Financiamento Bayer SA" Limpar

Filtros

Autores USP
- chiann, chang (2)
- bohatch júnior, milton sérgio (1)
- fonseca, benedito antonio lopes da (1)
- joviliano, edwaldo edner (1)
- ribeiro, maurício serra (1)

Artigo de periodico
Rivaroxaban for patients with intermittent claudication (2024)
Ramacciotti, Eduardo ; Volpiani, Giuliano Giova ; Britto, Karen Falcão; Agati, Leandro Barile ; Ribeiro, Camilla Moreira ; Aguiar, Valéria Cristina Resende ; Paganotti, Alexia ; Pereira, Felipe Menegueti; Caffaro, Roberto Augusto ; Krakauer, Rogério ; Rached, Heron Rhydan Saad ; Fareed, Jawed ; Wolosker, Nelson ; Anand, Sonia S. ; Eikelboom, John W. ; Chang, Chiann ; Lopes, Renato D
Fonte: NEJM Evidence. Unidades: FM, IME
Assunto: ESTATÍSTICA APLICADA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RAMACCIOTTI, Eduardo et al. Rivaroxaban for patients with intermittent claudication. NEJM Evidence, v. 3, n. 9, p. 1, 2024Tradução . . Disponível em: https://doi.org/10.1056/EVIDoa2400021. Acesso em: 02 nov. 2025.
APA
Ramacciotti, E., Volpiani, G. G., Britto, K. F., Agati, L. B., Ribeiro, C. M., Aguiar, V. C. R., et al. (2024). Rivaroxaban for patients with intermittent claudication. NEJM Evidence, 3( 9), 1. doi:10.1056/EVIDoa2400021
NLM
Ramacciotti E, Volpiani GG, Britto KF, Agati LB, Ribeiro CM, Aguiar VCR, Paganotti A, Pereira FM, Caffaro RA, Krakauer R, Rached HRS, Fareed J, Wolosker N, Anand SS, Eikelboom JW, Chang C, Lopes RD. Rivaroxaban for patients with intermittent claudication [Internet]. NEJM Evidence. 2024 ; 3( 9): 1.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1056/EVIDoa2400021
Vancouver
Ramacciotti E, Volpiani GG, Britto KF, Agati LB, Ribeiro CM, Aguiar VCR, Paganotti A, Pereira FM, Caffaro RA, Krakauer R, Rached HRS, Fareed J, Wolosker N, Anand SS, Eikelboom JW, Chang C, Lopes RD. Rivaroxaban for patients with intermittent claudication [Internet]. NEJM Evidence. 2024 ; 3( 9): 1.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1056/EVIDoa2400021
Artigo de periodico
Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial (2022)
Ramacciotti, Eduardo ; Agati, Leandro Barile ; Calderaro, Daniela ; Aguiar, Valéria Cristina Resende ; Spyropoulos, Alex C ; Oliveira, Caroline Candida Carvalho de; Santos, Jessica Lins dos; Volpiani, Giuliano Giova ; Sobreira, Marcone Lima ; Joviliano, Edwaldo Edner ; Bohatch Júnior, Milton Sérgio ; Fonseca, Benedito Antonio Lopes da ; Ribeiro, Maurício Serra; Dusilek, Cesar ; Itinose, Kenji ; Sanches, Suzanna Maria Viana ; Ramos, Karine de Almeida Araujo; Moraes, Nara Franzin de; Tierno, Paulo Fernando Guimarães Morando Marzocchi ; Oliveira, André Luiz Menezes de ; Tachibana, Adriano ; Chate, Rodrigo Caruso ; Santos, Marcus Vinícius Barbosa; Cavalcante, Bruno Bezerra de Menezes ; Moreira, Ricardo Cesar Rocha ; Chiann, Chang ; Tafur, Alfonso ; Fareed, Jawed ; Lopes, Renato D ; MICHELLE investigators
Fonte: The Lancet. Unidades: FMRP, IME
Assuntos: COVID-19, TROMBOCITOPENIA, BIOESTATÍSTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RAMACCIOTTI, Eduardo et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. The Lancet, v. 399, n. 10319, p. 50-59, 2022Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(21)02392-8. Acesso em: 02 nov. 2025.
APA
Ramacciotti, E., Agati, L. B., Calderaro, D., Aguiar, V. C. R., Spyropoulos, A. C., Oliveira, C. C. C. de, et al. (2022). Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. The Lancet, 399( 10319), 50-59. doi:10.1016/S0140-6736(21)02392-8
NLM
Ramacciotti E, Agati LB, Calderaro D, Aguiar VCR, Spyropoulos AC, Oliveira CCC de, Santos JL dos, Volpiani GG, Sobreira ML, Joviliano EE, Bohatch Júnior MS, Fonseca BAL da, Ribeiro MS, Dusilek C, Itinose K, Sanches SMV, Ramos K de AA, Moraes NF de, Tierno PFGMM, Oliveira ALM de, Tachibana A, Chate RC, Santos MVB, Cavalcante BB de M, Moreira RCR, Chiann C, Tafur A, Fareed J, Lopes RD, MICHELLE investigators. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial [Internet]. The Lancet. 2022 ; 399( 10319): 50-59.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/S0140-6736(21)02392-8
Vancouver
Ramacciotti E, Agati LB, Calderaro D, Aguiar VCR, Spyropoulos AC, Oliveira CCC de, Santos JL dos, Volpiani GG, Sobreira ML, Joviliano EE, Bohatch Júnior MS, Fonseca BAL da, Ribeiro MS, Dusilek C, Itinose K, Sanches SMV, Ramos K de AA, Moraes NF de, Tierno PFGMM, Oliveira ALM de, Tachibana A, Chate RC, Santos MVB, Cavalcante BB de M, Moreira RCR, Chiann C, Tafur A, Fareed J, Lopes RD, MICHELLE investigators. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial [Internet]. The Lancet. 2022 ; 399( 10319): 50-59.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/S0140-6736(21)02392-8

Biblioteca Digital de Produção Intelectual da Universidade de São Paulo 2012 - 2025